

# Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

## SARS-CoV-2 Nucleocapsid Chimeric Recombinant Human Monoclonal Antibody (1A6)

RRID:AB\_2866554

Type: Antibody

### Proper Citation

Thermo Fisher Scientific Cat# MA5-35942, RRID:AB\_2866554

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2866554](http://antibodyregistry.org/AB_2866554)

**Proper Citation:** Thermo Fisher Scientific Cat# MA5-35942, RRID:AB\_2866554

**Target Antigen:** SARS-CoV-2 Nucleocapsid Chimeric

**Host Organism:** human

**Clonality:** recombinant monoclonal

**Comments:** Discontinued: 2024; Applications: ELISA (1:10,000-1:50,000), LF (1:500-1:2,000)

**Antibody Name:** SARS-CoV-2 Nucleocapsid Chimeric Recombinant Human Monoclonal Antibody (1A6)

**Description:** This recombinant monoclonal targets SARS-CoV-2 Nucleocapsid Chimeric

**Target Organism:** virus

**Clone ID:** clone 1A6

**Antibody ID:** AB\_2866554

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** MA5-35942

**Record Creation Time:** 20231110T031953+0000

**Record Last Update:** 20260829T193828+0000

### Ratings and Alerts

No rating or validation information has been found for SARS-CoV-2 Nucleocapsid Chimeric Recombinant Human Monoclonal Antibody (1A6).

No alerts have been found for SARS-CoV-2 Nucleocapsid Chimeric Recombinant Human Monoclonal Antibody (1A6).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Buckner CM, et al. (2022) Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. Cell, 185(23), 4333.